BA
The Boeing Company
BA has a slight edge over TBI overall, supported by lower modeled downside and stronger fundamentals.
TBI
TrueBlue, Inc.
TBI offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
TBI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Weak |
TBI's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
TBI PE Valuation
TBI has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
TBI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TBI to return to profit, with revenue growing.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has the edge over TBI on earnings quality, reporting a profit while its opponent remains loss making.
TBI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.69 | — |
| Q3 2026 | -$1.55 | -$0.59 |
| Q2 2026 | -$1.89 | -$0.73 |
| Q1 2026 | -$1.79 | +$2.81 |
| Q4 2025 | -$1.61 | +$2.56 |
| Q3 2025 | -$0.96 | +$2.88 |
| Q2 2025 | -$1.16 | +$2.42 |
| Q1 2025 | -$4.60 | -$4.23 |
| Q4 2024 | -$4.17 | -$3.72 |
TBI is still losing money, but far less than before: $1.55 per share over the past year, against $4.60 at its worst in early 2025.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA has the edge over TBI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA's operating margin was 1.5% last quarter, up 22 points from the same quarter a year ago.
TBI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $520.7M | +21% |
| Q2 2026 | $443M | +12% |
| Q1 2026 | $398.6M | +7.6% |
| Q4 2025 | $418.2M | +8.3% |
| Q3 2025 | $431.3M | +13% |
| Q2 2025 | $396.3M | 0% |
| Q1 2025 | $370.3M | -8.1% |
| Q4 2024 | $386M | -22% |
TBI's revenue is recovering but still below its 2021 peak: $521M last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.3% | +2.3 points |
| Q2 2026 | -0.3% | +0.5 points |
| Q1 2026 | -4.5% | -0.7 points |
| Q4 2025 | -7% | -4.3 points |
| Q3 2025 | 0% | +1.8 points |
| Q2 2025 | -0.7% | +14 points |
| Q1 2025 | -3.8% | 0 points |
| Q4 2024 | -2.7% | -1 points |
TBI has the edge over BA on profitability, with a higher operating margin.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over TBI on cash generation, producing positive trailing cash flow while its opponent burns cash.
TBI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.3M | -$4.9M |
| Q2 2026 | -$24M | -$7.9M |
| Q1 2026 | -$12.6M | +$14.2M |
| Q4 2025 | -$7.5M | -978% |
| Q3 2025 | -$23.4M | -$10.7M |
| Q2 2025 | -$16.1M | -$8.3M |
| Q1 2025 | -$26.8M | -$5.2M |
| Q4 2024 | $854K | -88% |
TBI has burned cash in seven of the last eight quarters: −$72M over the past year, against −$65M the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has the edge over TBI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
TBI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.3% | +2.2M shares |
| 1 year | +9.2% | +2.7M shares |
| 3 years | +5.5% | +1.7M shares |
| 5 years | -8% | -2.8M shares |
| Available history | -17% | -6.5M shares |
TBI has 33M diluted shares, up 9.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $8,000 |
| Q3 2024 | $4.3M |
| Q2 2024 | $6.9M |
| Q1 2024 | $10.1M |
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
TBI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 929.0x | High |
| Q4 2023 | -31.4x | Net Cash |
| Q3 2023 | -2.7x | Net Cash |
| Q2 2023 | -1.1x | Net Cash |
| Q1 2023 | -0.6x | Net Cash |
| Q4 2022 | -0.7x | Net Cash |
| Q3 2022 | -0.4x | Net Cash |
| Q2 2022 | -0.3x | Net Cash |
TBI's net debt is more than 20 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
TBI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 74.6 | Neutral |
TBI's weekly RSI is 71 (overbought) and its Stochastic is 75 (neutral).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA is trading at 18x earnings, a 26% discount to the Industrials sector's median of 24x, though its earnings don't support one.
TBI PE vs Industrials Sector
| Metric | TBI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
TBI has no meaningful PE right now: it lost money over the past year.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
TBI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.92 | 24% above |
| 20 week MA | $9.34 | 32% above |
| 50 week MA | $6.73 | 84% above |
| 100 week MA | $6.42 | 92% above |
| 200 week MA | $9.78 | 26% above |
TBI has the edge over BA on trend strength, trading above more of its moving averages.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has finished lower in four of the last six years. It's down 21% so far in 2026.
TBI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.6 | $19.2 | -19% |
| 2021 | $19.2 | $27.7 | +44% |
| 2022 | $27.7 | $19.2 | -30% |
| 2023 | $19.2 | $15.3 | -20% |
| 2024 | $15.3 | $7.87 | -49% |
| 2025 | $7.87 | $4.65 | -41% |
| 2026 YTD | $4.65 | $12.4 | +166% |
TBI has the edge over BA on returns for 2026, with the stronger performance.